Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer

NCT ID: NCT07188116

Last Updated: 2025-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients. Breast cancer patients who underwent radiotherapy at the Cancer Center of Zhejiang Hospital between January 1, 2021, and June 30, 2024, were screened for eligibility. Patients who met the inclusion criteria were identified through the hospital information system, and their clinical records were reviewed. Follow-up was conducted via telephone interviews.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Radiation Pneumonia COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Without COVID-19

No COVID-19 infection

COVID-19

Intervention Type OTHER

The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.

With COVID-19

With COVID-19 infection

COVID-19

Intervention Type OTHER

The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19

The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients with pathologically or cytologically confirmed primary breast cancer,
2. aged 18 years or older but younger than 80 years,
3. with complete and reliable medical records,
4. for those with COVID-19 infection, documented evidence of a positive test result.

Exclusion Criteria

1. concomitant pulmonary malignancies,
2. a history of prior thoracic radiotherapy,
3. concurrent pulmonary infections other than COVID-19 during radiotherapy,
4. missing key data with loss to follow-up,
5. or any other condition considered unsuitable for enrollment by the investigators.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhejiang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030

Hangzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pengyuan Liu

Role: CONTACT

18368846455

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pengyuan Liu

Role: primary

18368846455

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COBRA-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.